AxoGen (AXGN)
(Delayed Data from NSDQ)
$6.27 USD
+0.16 (2.62%)
Updated May 24, 2024 04:00 PM ET
After-Market: $6.28 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
AxoGen, Inc. [AXGN]
Reports for Purchase
Showing records 61 - 71 ( 71 total )
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Recent Trends Bode Well for Our Covered Names Reporting This Week
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Medical Devices - 2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15 Remains Positive
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Encouraging Results from Pilot Study Evaluating Avance in da Vinci Prostatectomies
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Solid 1Q; Expect Positive Momentum to Continue in 2015
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
1Q15 Preview: Trends Look Better Than Initially Expected
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Initiating Coverage with an OUTPERFORM and a $5 PT; Reshaping the World of Peripheral Nerve Reconstruction
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
We are initiating coverage on shares with a BUY rating
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R